Brian M. Kopec
YOU?
Author Swipe
View article: Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles
Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles Open
Although doxorubicin (DOX) is an effective anti-cancer drug with cytotoxicity in a variety of different tumors, its effectiveness in treating glioblastoma multiforme (GBM) is constrained by insufficient penetration across the blood–brain b…
View article: Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice
Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice Open
Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) have been demonstrated for their potential as a neuroregenerative treatment of Alzheimer's disease (AD). Unfortunately, most proteins canno…
View article: Brain delivery of BDNF and a monoclonal antibody for the treatment of neurodegenerative animal models
Brain delivery of BDNF and a monoclonal antibody for the treatment of neurodegenerative animal models Open
There are a large number of protein-based therapeutics (biologics) that are FDA approved and available on the market for a number of diseases, and the number of biologics being approved every year has tripled in the past two decades. Biolo…
View article: Noninvasive Brain Delivery and Efficacy of BDNF to Stimulate Neuroregeneration and Suppression of Disease Relapse in EAE Mice
Noninvasive Brain Delivery and Efficacy of BDNF to Stimulate Neuroregeneration and Suppression of Disease Relapse in EAE Mice Open
The number of FDA-approved protein drugs (biologics), such as antibodies, antibody-drug conjugates, hormones, and enzymes, continues to grow at a rapid rate; most of these drugs are used to treat diseases of the peripheral body. Unfortunat…
View article: Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides
Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides Open
Many proteins can be used to treat brain diseases; however, the presence of the blood–brain barrier (BBB) creates an obstacle to delivering them into the brain. Previously, various molecules were delivered through the paracellular pathway …
View article: <i>In Vivo</i> Brain Delivery and Brain Deposition of Proteins with Various Sizes
<i>In Vivo</i> Brain Delivery and Brain Deposition of Proteins with Various Sizes Open
It is very challenging to develop protein drugs for the treatment of brain diseases; this is due to the difficulty in delivering them into the brain because of the blood-brain barrier (BBB). Thus, alternative delivery methods need further …
View article: Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors
Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors Open
The blood-brain barrier (BBB) poses a major obstacle by preventing potential therapeutic agents from reaching their intended brain targets at sufficient concentrations. While transient disruption of the BBB has been used to enhance chemoth…